Drug Profile
Eribulin mesylate - Eisai Co Ltd
Alternative Names: B-1939; B-1939 mesylate; E-7386; E-7389; ER-086526; Eribrin; Halaven; Halichondrin B Analog; NSC-707389; TECERISLatest Information Update: 19 Feb 2024
Price :
$50
*
At a glance
- Originator Eisai Co Ltd; Harvard University; Japan Agency for Medical Research and Development
- Developer Academic and Community Cancer Research United; Asan Medical Center; Big Ten Cancer Research Consortium; Eisai Co Ltd; Emory University; Icahn School of Medicine at Mount Sinai; Medica Scientia Innovation Research; Merck & Co; National Cancer Center Hospital East; National Cancer Institute (USA); Pfizer; PRISM Pharma Co
- Class 2 ring heterocyclic compounds; Antineoplastics; Cyclic ethers; Furans; Ketones; Macrocyclic compounds; Small molecules
- Mechanism of Action Apoptosis stimulants; Cadherin modulators; Receptor protein-tyrosine kinase modulators; Transcription factor modulators; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Breast cancer; Soft tissue sarcoma
- Phase III Non-small cell lung cancer
- Phase II Ewing's sarcoma; Glioblastoma; Haemangioendothelioma; Haemangiosarcoma
- Phase I/II Colorectal cancer; Liver cancer; Malignant melanoma; Solid tumours
- No development reported Ovarian cancer; Urogenital cancer
- Discontinued Bladder cancer; Prostate cancer
Most Recent Events
- 05 Dec 2023 Updated efficacy data from a phase Ib/II ENHANCE-1 trial in Breast cancer presented at the 46th Annual San Antonio Breast Cancer Symposium (SABCS-2023)
- 24 Nov 2023 Eisai withdraw a phase I trial (In volunteers) in UK (PO), due to delay in availability of the IMP (NCT04840927) (EudraCT2020-005638-13)
- 31 Aug 2023 Eisai completes a phase I pharmacokinetic trial (In volunteers) in the United Kingdom (PO, Tablet) (NCT05607537; EudraCT2022-000954-27)